Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646417 | 0.91 | PTPN1 (0.56) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL647675 | 0.91 | PTPN1 (0.57) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL647629 | 0.91 | PTPN1 (0.64) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL648320 | 0.89 | PTPN1 (0.57) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL646531 | 0.88 | PTPN1 (0.56) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL647626 | 0.88 | PTPN1 (0.59) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL646001 | 0.88 | PTPN1 (0.61) | PTPN1PTPN2ADRA2AADRA2BADRA2C | |
| SCHEMBL646967 | 0.87 | PTPN1 (0.57) | PTPN1PTPN2ADRB3 | |
| SCHEMBL646566 | 0.84 | PTPN1 (0.57) | PTPN1PTPN2MPOIDH1 | |
| SCHEMBL647121 | 0.84 | PTPN1 (0.57) | PTPN1PTPN2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885PTPN2 49/4885MPO 4459/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885PTPN2 39/4885MPO 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.